REGN Regeneron Pharmaceuticals Inc

Price (delayed)

$496.75

Market cap

$52.93B

P/E Ratio

13.22

Dividend/share

N/A

EPS

$37.57

Enterprise value

$54.18B

Sector: Healthcare
Industry: Biotechnology

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Tarrytown, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities , it ...

Highlights

The company's EPS has surged by 80% YoY and by 15% QoQ
Regeneron Pharmaceuticals's net income has surged by 76% YoY and by 14% QoQ
The quick ratio has contracted by 29% YoY and by 16% from the previous quarter

Key stats

What are the main financial stats of REGN
Market
Shares outstanding
106.54M
Market cap
$52.93B
Enterprise value
$54.18B
Valuations
Price to earnings (P/E)
13.22
Price to book (P/B)
4.44
Price to sales (P/S)
5.69
EV/EBIT
12.15
EV/EBITDA
11.51
EV/Sales
5.89
Earnings
Revenue
$9.2B
EBIT
$4.46B
EBITDA
$4.71B
Free cash flow
$2.03B
Per share
EPS
$37.57
Free cash flow per share
$19.25
Book value per share
$111.8
Revenue per share
$87.26
TBVPS
$168.62
Balance sheet
Total assets
$17.77B
Total liabilities
$5.8B
Debt
$2.7B
Equity
$11.98B
Working capital
$6.84B
Liquidity
Debt to equity
0.23
Current ratio
3.12
Quick ratio
2.39
Net debt/EBITDA
0.27
Margins
EBITDA margin
51.2%
Gross margin
86.8%
Net margin
43.5%
Operating margin
43.4%
Efficiency
Return on assets
24.5%
Return on equity
38%
Return on invested capital
31.5%
Return on capital employed
30.6%
Return on sales
48.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

REGN stock price

How has the Regeneron Pharmaceuticals stock price performed over time
Intraday
-0.39%
1 week
3.21%
1 month
3.11%
1 year
-11.27%
YTD
2.82%
QTD
4.99%

Financial performance

How have Regeneron Pharmaceuticals's revenue and profit performed over time
Revenue
$9.2B
Gross profit
$7.99B
Operating income
$3.99B
Net income
$4B
Gross margin
86.8%
Net margin
43.5%
Regeneron Pharmaceuticals's net income has surged by 76% YoY and by 14% QoQ
The operating income has soared by 64% YoY and by 12% QoQ
The net margin has increased by 34% YoY and by 5% from the previous quarter
The revenue has increased by 31% YoY and by 8% QoQ

Growth

What is Regeneron Pharmaceuticals's growth rate over time

Valuation

What is Regeneron Pharmaceuticals stock price valuation
P/E
13.22
P/B
4.44
P/S
5.69
EV/EBIT
12.15
EV/EBITDA
11.51
EV/Sales
5.89
The company's EPS has surged by 80% YoY and by 15% QoQ
REGN's price to earnings (P/E) is 52% lower than its 5-year quarterly average of 27.6 and 24% lower than its last 4 quarters average of 17.4
REGN's price to book (P/B) is 27% less than its 5-year quarterly average of 6.1 and 21% less than its last 4 quarters average of 5.6
The equity has grown by 9% since the previous quarter
The revenue has increased by 31% YoY and by 8% QoQ
The P/S is 24% lower than the 5-year quarterly average of 7.5 and 20% lower than the last 4 quarters average of 7.1

Efficiency

How efficient is Regeneron Pharmaceuticals business performance
Regeneron Pharmaceuticals's return on equity has surged by 81% YoY and by 14% QoQ
The return on assets has surged by 55% year-on-year and by 10% since the previous quarter
Regeneron Pharmaceuticals's return on invested capital has increased by 43% YoY and by 8% QoQ
The company's return on sales rose by 32% YoY and by 7% QoQ

Dividends

What is REGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for REGN.

Financial health

How did Regeneron Pharmaceuticals financials performed over time
Regeneron Pharmaceuticals's total liabilities has surged by 60% YoY but it has decreased by 6% QoQ
The quick ratio has contracted by 29% YoY and by 16% from the previous quarter
The debt is 77% less than the equity
The equity has grown by 9% since the previous quarter
REGN's debt to equity is down by 4.2% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.